IOL Chemicals & Pharmaceuticals Ltd
IOL Chemicals Q2 FY27 Standalone Net Profit at Rs. 65.03 Crore
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 30 Oct 2026, 05:59 PM IST · BSE ID: 6ec026a8-f682-46b4-8c1b-341dfbabf820
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's latest financial report shows significant increases in sales and profits for the quarter and half-year ended September 2026.
🤖 AI Summary
- IOL Chemicals reported Q2 FY27 standalone revenue from operations of Rs. 795.03 Crore.
- Standalone net profit for Q2 FY27 stood at Rs. 65.03 Crore, up from Rs. 30.00 Crore in Q2 FY26.
- Half-year ended 30 September 2026 revenue from operations reached Rs. 1,551.29 Crore.
- Half-year net profit was Rs. 129.51 Crore, compared to Rs. 63.96 Crore for the prior half-year.
- Basic and Diluted Earnings Per Share for Q2 FY27 was Rs. 2.21 per share.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Q2 FY27)
795.03 Crore
40.09%
Profit for the period (Q2 FY27)
65.03 Crore
116.77%
Basic and Diluted EPS (Q2 FY27)
2.21
116.67%
Revenue from operations (Half-year FY27)
1,551.29 Crore
38.60%
Profit for the period (Half-year FY27)
129.51 Crore
102.49%
Total Assets (as at 30-Sep-2026)
2,830.44 Crore
🏢 How This Affects the Company
Revenue from operations for Q2 FY27 increased to Rs. 795.03 Crore from Rs. 567.53 Crore in Q2 FY26, indicating expanded business activity. The Pharmaceutical segment continued to be the largest contributor to segment revenue.
Net profit for Q2 FY27 rose to Rs. 65.03 Crore from Rs. 30.00 Crore in Q2 FY26, improving profitability. Total assets increased to Rs. 2,830.44 Crore as of 30 September 2026 from Rs. 2,586.72 Crore on 31 March 2026.
Capital work-in-progress increased to Rs. 189.40 Crore as of 30 September 2026 from Rs. 93.61 Crore on 31 March 2026, suggesting ongoing capacity expansion or modernization efforts. Inventories increased to Rs. 464.38 Crore from Rs. 371.07 Crore over the same period.
Current borrowings increased to Rs. 194.16 Crore as of 30 September 2026 from Rs. 132.00 Crore on 31 March 2026, indicating increased reliance on short-term financing.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the improved financial performance, with Q2 FY27 Basic and Diluted EPS reported at Rs. 2.21 per share.
🔍
Management Signal
The approval and submission of unaudited financial results indicate a continued focus on operational performance and compliance with regulatory disclosure requirements.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q3 FY27 results — monitor sustained revenue and profit growth trends.
Capital expenditure updates — track progress on capital work-in-progress.
Debt levels — observe changes in current and non-current borrowings.
MEDIUM RISK
While profit grew, the significant reduction in cash and cash equivalents, alongside increased current borrowings, warrants attention.
💡 Investor Takeaway
IOL Chemicals & Pharmaceuticals reported Q2 FY27 standalone revenue from operations of Rs. 795.03 Crore, an increase from Rs. 567.53 Crore in Q2 FY26. Net profit for the quarter rose to Rs. 65.03 Crore from Rs. 30.00 Crore YoY, while half-year net profit reached Rs. 129.51 Crore.
⚖️ Strengths & Concerns
✅ Positives
- Revenue from operations for Q2 FY27 significantly increased to Rs. 795.03 Crore, up from Rs. 567.53 Crore in Q2 FY26.
- Net profit for Q2 FY27 more than doubled to Rs. 65.03 Crore, compared to Rs. 30.00 Crore in Q2 FY26.
⚠️ Concerns
- Cash and cash equivalents decreased significantly to Rs. 9.20 Crore as of 30 September 2026 from Rs. 65.29 Crore on 31 March 2026.
- Current borrowings rose to Rs. 194.16 Crore from Rs. 132.00 Crore, indicating higher short-term debt.
❓ Frequently Asked Questions
What was IOL Chemicals & Pharmaceuticals' revenue from operations in Q2 FY27?
IOL Chemicals & Pharmaceuticals reported standalone revenue from operations of Rs. 795.03 Crore for the quarter ended 30 September 2026.
What was IOL Chemicals & Pharmaceuticals' net profit for Q2 FY27?
The standalone net profit for IOL Chemicals & Pharmaceuticals for Q2 FY27 was Rs. 65.03 Crore, compared to Rs. 30.00 Crore in Q2 FY26.
How much was IOL Chemicals & Pharmaceuticals' Basic and Diluted EPS in Q2 FY27?
IOL Chemicals & Pharmaceuticals reported a Basic and Diluted Earnings Per Share of Rs. 2.21 for the quarter ended 30 September 2026.
What were IOL Chemicals & Pharmaceuticals' total assets as of 30 September 2026?
As of 30 September 2026, IOL Chemicals & Pharmaceuticals' total standalone assets stood at Rs. 2,830.44 Crore.
What was IOL Chemicals & Pharmaceuticals' net cash flow from operating activities for the half-year ended 30 September 2026?
Net cash flow from operating activities for IOL Chemicals & Pharmaceuticals was Rs. 8.32 Crore for the half-year ended 30 September 2026.
Questions based on this BSE filing only. For information purposes.